Lower Tx Dose in Ankylosing Spondylitis Possible
Dose reduction may mean substantial savings with minimal clinical risk
medpagetoday.com
Long-term TNFi tapering possible for some with ankylosing spondylitis
BIRMINGHAM, ENGLAND – A proportion of patients with ankylosing spondylitis (AS) were able to remain on a reduced-dose regimen of a tumor necrosis factor inhibitor (TNFi) for almost 4 years, according to data from a small study presented at the British Society for Rheumatology annual confer…
mdedge.com